MIST Stock Summary and Trading Ideas (Milestone Pharmaceuticals - Common Shares | NASDAQ:MIST)

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Milestone Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol MIST.

As of January 9, 2026, MIST stock price declined to $2.04 with 6,192,570 million shares trading.

MIST has a beta of 2.23, meaning it tends to be more sensitive to market movements. MIST has a correlation of 0.12 to the broad based SPY ETF.

MIST has a market cap of $173.75 million. This is considered a Micro Cap stock.

Last quarter Milestone Pharmaceuticals - Common Shares reported $0 in Revenue and -$.12 earnings per share. This fell short of revenue expectation by $-400,000 and exceeded earnings estimates by $.05.

In the last 3 years, MIST traded as high as $4.49 and as low as $.63.

The top ETF exchange traded funds that MIST belongs to (by Net Assets): GWX, QQQS.

MIST has underperformed the market in the last year with a price return of -7.3% while the SPY ETF gained +19.0%. MIST has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.4% and -1.9%, respectively, while the SPY returned +3.7% and +0.5%, respectively.

MIST support price is $2.05 and resistance is $2.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MIST shares will trade within this expected range on the day.